This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Levetiracetam Treatment of Tardive Dyskinesia

This study has been completed.
UCB Pharma
Information provided by (Responsible Party):
Yale University Identifier:
First received: February 10, 2006
Last updated: June 5, 2014
Last verified: June 2014
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Condition Intervention Phase
Tardive Dyskinesia Drug: levetiracetam Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Abnormal Involuntary Movement Scale (AIMS) Total Score [ Time Frame: 12 weeks ]

Enrollment: 50
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levetiracetram Administration Drug: levetiracetam
Placebo Comparator: Placebo Drug: placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: meet Glazer Morgenstern criteria for TD -

Exclusion Criteria: none

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00291213

United States, Connecticut
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
UCB Pharma
Principal Investigator: Scott W Woods, MD Yale School of Medicine
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yale University Identifier: NCT00291213     History of Changes
Other Study ID Numbers: YaleHIC26585
Study First Received: February 10, 2006
Last Updated: June 5, 2014

Additional relevant MeSH terms:
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs processed this record on September 21, 2017